• Home

Home > Medical Reference > Patient Education

• Highlights
• Introduction
• Symptoms
• Causes of Benign Prostatic Hyperplasia
• Causes of Lower Urinary Tract Symptoms
• Risk Factors
• Complications
• Diagnostic Tests
• Treatment
• Lifestyle Changes
• Medications
• Other Treatments
• Resources
• References

Benign prostatic hyperplasia

Description

An in-depth report on the causes, diagnosis, treatment, and prevention of BPH.

Alternative Names

Enlarged prostate

References

Andriole GL, Marberger M, Roehrborn CG. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride. J Urol . 2006;175(5):1657-1662.

Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med . 2006;354(6):557-566.

Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol . 2006;175(1):217-220.

MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology . 2005;66(4):780-788.

Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int . 2006;97(4):734-741.

Rule AD, Jacobson DJ, Roberts RO, Girman CJ, McGree ME, Lieber MM, et al. The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int . 2005;67(6):2376-2382.

Schulman C, Pommerville P, Hofner K, Wachs B. Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. BJU Int . 2006;97(1):73-79.

• Review Date: 6/26/2006
• Reviewed By: Harvey Simon, MD, Editor-in-Chief, Associate Professor of Medicine, Harvard Medical School; Physician, Massachusetts General Hospital

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process . A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997-2007 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.